Onychomycosis Market

DelveInsight’s ‘Onychomycosis – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), China and Japan.

The Onychomycosis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Onychomycosis symptoms market size from 2018 to 2030. The report also covers current Onychomycosis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geographies Covered

• The United States
• EU5
• Japan
• China

Study Period: 2018–2030

Onychomycosis Disease Understanding and Treatment Algorithm

Onychomycosis Overview

Onychomycosis is a common fungal nail infection that has been estimated to account for about half of all nail diseases. Although not life-threatening, fungal nail infections are an important public health concern due to their high prevalence, poor response to therapy, and significant clinical, social and financial impact.

In Western countries, 80–90% of Onychomycosis cases are primarily caused by dermatophytes, with 5–17% due to yeasts and 2–3% due to non-dermatophyte molds. The high prevalence of fungal infections in North America is largely due to the immigration of dermatophytes from other areas of the world, such as West Africa and Southeast Asia.

Patients with Onychomycosis often complain of nail discoloration, nail separation, brittleness, or thickening that often worsens with time. A history of tinea pedis or hyperhidrosis of the feet is common. Nails affected by Onychomycosis may cause local pain, difficulty fitting shoes and employment, social embarrassment, and harm the quality of life.

Greater than 50% nail plate involvement, more than three nails involved, or presence of dermatophytosis, requires consideration of systemic therapy. Oral terbinafine (continuous or pulse) is usually the first choice of therapy. However, if there is less than 50% involvement of the diseased nail plate and less than three nails involved, topical therapy is an appropriate consideration. Efinaconazole 10%, ciclopirox 8% (once a day), amorolfine 5% (once a week), or tavaborole 5% are the preferred topical treatment options.

Onychomycosis Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the Onychomycosis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the 7MM+China.

The DelveInsight Onychomycosis market report thoroughly understands Onychomycosis symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Onychomycosis symptoms of treatment algorithms and treatment guidelines for Onychomycosis symptoms in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan.

Onychomycosis Epidemiology

The epidemiology division’s Onychomycosis symptoms provide insights into the historical and current patient pool and the forecasted trend for every 7MM+China country. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Onychomycosis epidemiology segmented as the Diagnosed Prevalent Cases of Onychomycosis, Diagnosed Prevalent by Subtypes, Diagnosed Prevalent Cases of Onychomycosis by Severity, and Treated Cases of Onychomycosis. The report includes the prevalent Onychomycosis symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), China, and Japan from 2018 to 2030.

The total prevalent cases of Onychomycosis in the 7MM+China were 93,633,252 in 2020.

Onychomycosis Drug Chapters

The drug chapter segment of the Onychomycosis report encloses the detailed analysis of Onychomycosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Onychomycosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

The current treatment landscape can be divided into components based on routes of administration, namely; Systemic (Oral) and Topical Medications.

Currently, oral Terbinafine hydrochloride (Lamisil) is the most common treatment for Onychomycosis. These 250mg tablets are taken once a day for 12 weeks. First approved in 1996 by the US FDA, it has been the mainstay with all its generic versions marketed since the patent expiry in 2007. Other components that make up the total revenue generated by systemic therapies include Itraconazole, Griseofulvin, Fluconazole, and Ketoconazole. These components have been included in the forecast model to calculate the approximate revenue estimates during the study period [2018–2030].

Products detail in the report…

Onychomycosis Emerging Drugs

One major player is Moberg Pharma, with its leading product MOB-015. It is a next-generation nail fungus treatment targeting both the over-the-counter (OTC) and prescription markets. The company’s patented technology facilitates the delivery of high concentrations of terbinafine into and through the nail. Therefore, this compound has generated enough buzz already in the market since it can address the unmet need for better topical treatments without the risk of systemic side effects.

Onychomycosis Market Outlook

The Onychomycosis market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Onychomycosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Onychomycosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

According to DelveInsight, the Onychomycosis market in the 7MM+China is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Onychomycosis market in the United States. The market size of Onychomycosis in 7MM+China was USD 1,278.4 Million in 2020, and the market is estimated to increase during the study period (2018–2030).

The United States Market Outlook

This section provides a total of Onychomycosis market size and market size by therapies in the United States.

The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for Onychomycosis are in development, many of which have novel targets and mechanisms of action. Among the biologics, Blueberry Therapeutics’ BB2603 and Mycovia Pharmaceuticals’ VT-1161 are in the late development stages.

Blueberry Therapeutics’ drug candidate, BB2603, has received investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development to treat Onychomycosis. The company uses its potent nanotechnology-based topical drug delivery platform to maintain the efficacy of the oral gold standard treatment but at a lower dose. Targeted delivery by penetrating the nail bed ensures lower dosage and reduced systemic side effects.

EU-5 Countries: Market Outlook

The total Onychomycosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided.

Novexatin (NP213) being developed by NovaBiotics, is another such candidate whose developmental status is currently under speculation due to certain technological developments. Although the active compound NP213 is a novel, synthetic antimicrobial peptide (AMP) generated from NovaBiotics’ rational drug design technology platform and have demonstrated safety and efficacy profiles as per company’s reports, the mutual termination of a license agreement with Taro Pharmaceuticals in 2018 has cast a shadow on its developmental pathway. 

Japan: Market Outlook

The total Onychomycosis market size and market size by therapies in Japan are also mentioned.

Onychomycosis Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Onychomycosis market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Onychomycosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Onychomycosis key players involved in developing targeted therapeutics.

Major players include Blueberry Therapeutics’ BB2603 and Moberg Pharma’s MOB-015 being assessed as potential therapies available in the market in the future.

Products detail in the report…

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Onychomycosis emerging therapies.

Reimbursement Scenario in Onychomycosis

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do their best to ensure that the patient receives Social Security Disability benefits as quickly as possible and help the patient avoid the lengthy disability appeal process.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in Onychomycosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Onychomycosis market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Onychomycosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Onychomycosis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Onychomycosis epidemiology and treatment in the  United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan
• Additionally, an all-inclusive account of both the current and emerging therapies for Onychomycosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Onychomycosis market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), China and Japan
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Onychomycosis market

Report Highlights

• In the coming years, the Onychomycosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Onychomycosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Onychomycosis. The launch of emerging therapies will significantly impact the Onychomycosis market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Onychomycosis.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Onychomycosis Report Insights

• Patient Population
• Therapeutic Approaches
• Onychomycosis Pipeline Analysis
• Onychomycosis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Onychomycosis Report Key Strengths

• 10-Year Forecast
• 7MM+China Countries Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Market Size by Country
• Market Size by Therapy

Onychomycosis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Emerging Drug Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Onychomycosis Market share (%) distribution in 2018, and how would it look like in 2030?
• What would be the Onychomycosis total market size and market size by therapies across the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan during the forecast period (2018–2030)?
• What are the market’s key findings across the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan, and historical as well as forecasted epidemiology during the forecast period (2018–2030)?
• At what CAGR, the Onychomycosis market is expected to grow by the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan during the forecast period (2018–2030)?
• What would be the Onychomycosis market outlook across the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan during the forecast period (2018–2030)?
• What would be the Onychomycosis market growth till 2030, and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Onychomycosis?
• What is the historical Onychomycosis patient pool in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan?
• What would be the forecasted patient pool of Onychomycosis in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan?
• What will be the growth opportunities in the 7MM+China concerning the patient population about Onychomycosis?
• At what CAGR is the population expected to grow during the forecast period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Onychomycosis?
• What are the current treatment guidelines for treating Onychomycosis in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan?
• What are Onychomycosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Onychomycosis?
• How many therapies are developed by each company for the treatment of Onychomycosis?
• How many emerging therapies are in the mid-stage and late stages of development to treat Onychomycosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Onychomycosis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Onychomycosis and its status?
• What are the key designations that have been granted for the emerging therapies for Onychomycosis?
• What are the global historical and forecasted market of Onychomycosis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Onychomycosis market
• To understand the future market competition in the Onychomycosis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Onychomycosis in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Onychomycosis market
• To understand the future market competition in the Onychomycosis market